John Burke, MD
Hematology & Oncology · Aurora, CONPI 1801871215
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $222,812 of the $320,697 with a category attached, or 69.5%. It is spread thinly across 39 manufacturers, the largest accounting for just 23.5%. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $1303.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$76K
- Genentech, Inc.$55K
- Seagen Inc.$17K
- AbbVie$17K
- E.r. Squibb & Sons, L.L.C.$17K
- Genmab U.S., Inc.$15K
- plus $125K from 33 others
Across 4,332 payments — averaging $5801.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$9.1M
- Beigene, Ltd.$6.2M
- Astrazeneca UK Limited$2.5M
- AstraZeneca$1.4M
- Seagen Inc.$1.1M
- AbbVie$855K
- plus $3.9M from 19 others
What the payments were for
- Consulting fees$222,81269%
- Speaking & faculty fees$36,87711%
- Travel & lodging$55,28417%
- Food & beverage$5,5452%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 24 | $75,519 |
| Genentech, Inc. | 37 | $54,708 |
| Seagen Inc. | 20 | $17,046 |
| AbbVie | 19 | $16,991 |
| E.r. Squibb & Sons, L.L.C. | 12 | $16,823 |
| Genmab U.S., Inc. | 10 | $14,512 |
| Adaptive Biotechnologies Corporation | 6 | $12,015 |
| AstraZeneca | 11 | $11,812 |
| Genentech USA, Inc. | 12 | $10,486 |
| Beigene USA, Inc. | 7 | $10,183 |
| Morphosys AG | 6 | $8,171 |
| Bristol Myers Squibb | 10 | $7,530 |
| Ipsen Biopharmaceuticals, Inc | 3 | $6,680 |
| TG Therapeutics, Inc. | 10 | $6,500 |
| Novartis | 5 | $6,279 |
| Morphosys, US Inc. | 3 | $5,465 |
| Lilly USA, LLC | 3 | $4,494 |
| Astrazeneca UK Limited | 3 | $4,087 |
| Verastem, Inc. | 2 | $4,085 |
| Gilead(2 entities) | 8 | $4,057 |
| Beone Medicines USA, Inc. | 2 | $4,050 |
| ADC Therapeutics America, Inc. | 6 | $3,043 |
| Eli Lilly | 3 | $2,991 |
| Pfizer | 2 | $2,508 |
| Karyopharm Therapeutics Inc. | 1 | $2,325 |
| Incyte Corporation | 2 | $2,248 |
| Sanofi | 2 | $1,936 |
| Novartis Pharma AG | 2 | $1,436 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $1,375 |
| Epizyme, Inc. | 1 | $725 |
| Medtronic | 2 | $304 |
| Tempus AI, Inc | 1 | $94 |
| Amgen | 3 | $57 |
| Johnson & Johnson | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| CTI Biopharma Corp. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$320,697 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 418 | $8,985,702 |
| BrukinsaZanubrutinib | 164 | $2,349,341 |
| PomalystPomalidomide | 53 | $1,093,049 |
| VenclextaVenetoclax | 62 | $864,115 |
| Lenalidomide | 44 | $710,374 |
| JakafiRuxolitinib Phosphate | 61 | $649,947 |
| ImbruvicaIbrutinib | 43 | $599,277 |
| CalquenceAcalabrutinib Maleate | 20 | $299,498 |
| TasignaNilotinib Hcl | 13 | $261,852 |
| NinlaroIxazomib Citrate | 14 | $182,555 |
| ErleadaApalutamide | 11 | $151,896 |
| EliquisApixaban | 110 | $100,500 |
| InqoviDecitabine/Cedazuridine | 13 | $48,072 |
| XareltoRivaroxaban | 26 | $27,439 |
| Imatinib Mesylate | 31 | $22,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $7,530 | $8,985,702418 claims |
| Beigene USA, Inc.Brukinsa | $10,183 | $2,349,341164 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $16,823 | $1,093,04953 claims |
| AbbVieVenclexta | $16,991 | $864,11562 claims |
| Incyte CorporationJakafi | $2,248 | $649,94761 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $1,375 | $599,27743 claims |
| AstraZenecaCalquence | $11,812 | $299,49820 claims |
| NovartisTasigna | $6,279 | $261,85213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $29 | $182,55514 claims |
| Johnson & JohnsonErleada, Xarelto | $43 | $179,33637 claims |
| PfizerEliquis | $2,508 | $100,500110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Aurora
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.